Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.
Eli Lilly and Company broke ground on a $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley.
The site joins nine other new U.S. manufacturing sites Eli Lilly has announced since 2020, and is one of four among them dedicated to injectable medicines and devices. The project is part of the company’s $50 billion push to expand medicine production in the U.S., and the Lehigh Valley site is expected to add capacity for the next generation of obesity treatments, including retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple hormone receptor agonist.1…